Patients & Healthcare Professionals
News
Career
繁體中文
English
PharmaEssentia-Ropeginterferon alfa-2b,P1101,PV,polycythemia vera,new drug development,biologics,PIC/s GMP protein plant>
Mobile Button
Search>
About Us
Achievements
Management
Board
Partnership
Locations
Privacy and Cookies Policy
Focus
Hematology
P1101 in PV Phase III
P1101 in ET Phase III
Infectious Diseases
P1101 in HCV Phase III in Genotype 2 Study (A14-301)
P1101 in HBV Phase III Study in Biomarker Selected HBeAg+ Population (A17-301)
P1101 in HBV/HCV Co-Infection Study (A17-201)
Oncology
KX-ORAX-005 Oraxol in combination with Ramucirumab for Gastric, Gastro-esophageal or Esophageal Cancer
KX-ORAX-007 A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
PD-1 in HCC Phase I/II (IIT)
Dermatology
KX01 in Psoriasis
Resources
Capabilities
R&D Center
Pipeline
Core Technology
R&D Focus
Manufacturing Site
Milestone
Facilities
Process and Critical Equipment
Patients & Healthcare Professionals
Investors
Financial Information
Shareholder’s Services
Stock Information
Announcement
Investor Relations
企業社會責任專區
News
Latest News
Press Releases
Events
Contact
Language
繁體中文
English
404 Page Not Found
The page you requested was not found.
Back To Index
pharmaessentia